過敏診斷市場（按測試類型、技術、過敏原類型和最終用戶分類）—2025-2032 年全球預測

預計到 2032 年，過敏診斷市場規模將成長至 94.6 億美元，複合年成長率為 5.98%。

簡述影響現代過敏診斷策略的不斷變化的臨床需求和技術進步

過敏診斷處於臨床需求與技術創新的交匯點，其驅動力來自過敏性疾病盛行率的上升、臨床醫生診斷意識的提升以及患者對針對性管理策略的需求。臨床醫生越來越依賴精準的診斷途徑來區分致敏和臨床相關過敏，這使得在門診和住院環境中進行可重複、高品質的檢測變得尤為重要。同時，檢測技術和實驗室自動化的進步正在拓展可行的檢測方案，從而實現更細緻的解讀，並支持精準的治療方法。

醫療保健系統也在應對減少可避免的急診就診和改善慢性病管理的壓力，將準確快速的過敏診斷定位為更廣泛護理途徑中經濟高效的臨床工具。付款人和採購團隊要求提供臨床效用、營運效率以及與電子健康記錄互通性的證據，這促使供應商和實驗室優先考慮檢驗、標準化和報告清晰度。總而言之，這些趨勢明確了希望投資和採用過敏診斷解決方案的利害關係人的當務之急。

臨床、技術和操作趨勢的融合從根本上重塑了診斷途徑並實現了個人化過敏藥物。

技術日趨成熟、臨床模式不斷轉變以及醫療服務模式的不斷發展，正在顯著改變過敏診斷領域。分子診斷和成分解析診斷已從小眾應用走向更廣泛的臨床應用，使臨床醫生能夠分析複雜的致敏情況，並更好地預測嚴重過敏反應的風險。同時，多重平台的出現，加上偵測靈敏度和特異性的提升，正在減少診斷的不確定性，縮短治療決策的路徑。

在營運方面，診斷實驗室正在採用更高程度的自動化和數位化整合，以提高通量、縮短週轉時間，同時支援一致的品管。即時檢驗計劃和分散式檢測路徑反映了將適當的護理轉移到更貼近患者的更廣泛趨勢。此外，診斷結果與臨床決策支援工具的整合正變得越來越普遍，使臨床醫生能夠根據檢測結果、合併症概況和暴露史獲得循證建議。這種轉變正在將過敏診斷的作用從確認性檢測轉變為主動實現個人化護理。

評估 2025 年關稅格局將如何重塑診斷價值鏈的供應鏈、採購行為和區域製造策略

政策和貿易行動可能會對整個診斷供應鏈產生重大的連鎖反應，而2025年宣布的關稅調整的累積影響將波及製造、分銷和實驗室營運的各個環節。對進口試劑、儀器零件和耗材徵收關稅可能會提高依賴海外供應商的製造商的邊際生產成本，從而導致標價上漲和合約壓力。對於實驗室和最終用戶而言，這更凸顯了供應鏈韌性、庫存規劃和長期供應商協議談判的重要性。

此外，關稅可能會推動生產和採購的在地化，促使跨國製造商重新評估其採購佈局，並考慮近岸外包或雙重採購策略以降低風險。同時，醫院、門診中心和診斷網路內的採購團隊可能會將採購重點轉移到擁有國內生產能力或已製定關稅減免政策的供應商。這些調整可能會加速能夠吸收成本波動並維持服務水準的供應商之間的整合，同時迫使規模較小的供應商和試劑供應商最佳化營運或建立策略聯盟以保持市場進入。

有針對性的細分洞察，將機會與測試方式、檢測技術、過敏原和最終用戶業務優先事項聯繫起來

細分市場洞察對於客製化產品開發、商業化和應用策略至關重要。基於檢測類型的診斷途徑範圍廣泛，從基於皮膚的方法（例如皮內測試和斑貼測試）到基於血清的方法（包括血清特異性IgE檢測和皮膚點刺測試）。對於血清分析，化學冷光免疫檢測和酵素結合免疫吸附檢測法與傳統的放射性過敏原檢測法並存，每種方法在通量、靈敏度和實驗室相容性方面各有優缺點。化學冷光平台往往強調自動化和靈敏度，酵素結合免疫吸附分析為中型實驗室提供靈活性和成本效益，螢光酶聯免疫分析根據配置提供連接複用優勢，而放射性過敏原吸附分析在現有工作流程持續存在的情況下仍然具有重要意義。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• 基層醫療機構擴大採用照護現場過敏檢測設備
• 多重免疫檢測平台的快速成長提供了更廣泛的過敏原組
• 整合人工智慧和機器學習，提高過敏測試的診斷準確性
• 擴大採用成分解析診斷技術，以便對個別過敏原進行分析，從而進行標靶治療
• 擴展家庭過敏檢測套組，支援透過智慧型手機連接進行遠端患者監護
• 新興分子診斷技術可準確辨識過敏表位
• 數位醫療基礎設施的改善正在推動基於遠端醫療的過敏諮詢需求
• 不斷變化的監管環境影響創新過敏診斷解決方案的核准途徑

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章過敏診斷市場（依測試類型）

• 皮內試驗
• 斑貼試驗
• 血清特異性IgE檢測
  • 化學冷光免疫檢測
  • 酵素結合免疫吸附試驗
  • 放射性過敏原吸附試驗
• 皮膚點刺試驗

9. 過敏診斷市場（依技術）

• 化學冷光免疫檢測
• 酵素結合免疫吸附試驗
• 螢光酵素免疫分析法
• 放射性過敏原吸附試驗

第 10 章過敏診斷市場（依過敏原類型）

• 接觸過敏原
• 藥物過敏原
• 食物過敏原
• 吸入性過敏原

第 11 章過敏診斷市場（依最終用戶）

• 門診治療中心
• 診斷實驗室
• 醫院和診所

第12章過敏診斷市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第13章過敏診斷市場（依類別）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第14章 過敏診斷市場（依國家）

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第15章競爭格局

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Hycor Biomedical, LLC
  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Eurofins Scientific SE
  • Quest Diagnostics Incorporated
  • Stallergenes Greer, Inc.

The Allergy Diagnostics Market is projected to grow by USD 9.46 billion at a CAGR of 5.98% by 2032.

A concise orientation to the evolving clinical imperatives and technological advances shaping modern allergy diagnostic strategies

Allergy diagnostics sits at the nexus of clinical need and technological innovation, driven by rising prevalence of allergic conditions, greater diagnostic awareness among clinicians, and patient demand for targeted management strategies. Clinicians increasingly rely on precise diagnostic pathways to distinguish sensitization from clinically relevant allergy, and this has elevated the importance of reproducible, high-quality testing across outpatient and hospital settings. Concurrently, advances in assay technologies and laboratory automation have expanded the range of viable options, enabling more nuanced interpretations and supporting precision therapeutics.

Healthcare systems are also responding to pressures to reduce avoidable emergency visits and improve chronic disease management, which positions accurate and rapid allergy diagnostics as a cost-effective clinical tool in broader care pathways. Payers and procurement teams are seeking evidence of clinical utility, operational efficiency, and interoperability with electronic health records, prompting vendors and laboratories to prioritize validation, standardization, and reporting clarity. Taken together, these dynamics frame the immediate priorities for stakeholders seeking to invest in or adopt allergy diagnostic solutions.

How converging clinical, technological, and operational trends are fundamentally reshaping diagnostic pathways and enabling personalized allergy care

The landscape of allergy diagnostics is undergoing transformative shifts prompted by technological maturation, changing clinical paradigms, and evolving healthcare delivery models. Molecular and component-resolved diagnostics have moved from niche applications toward broader clinical acceptance, enabling clinicians to parse complex sensitization profiles and better predict risk for severe reactions. At the same time, improvements in assay sensitivity and specificity, alongside growing availability of multiplex platforms, are reducing diagnostic ambiguity and shortening the route to therapeutic decisions.

Operationally, diagnostic laboratories are adopting higher degrees of automation and digital integration, which improves throughput and reduces turnaround time while supporting consistent quality control. The rise of point-of-care initiatives and decentralized testing pathways reflects a broader trend toward shifting appropriate care closer to patients. Additionally, the integration of diagnostic outputs with clinical decision support tools is gaining traction, providing clinicians with evidence-based recommendations informed by test results, comorbidity profiles, and exposure histories. These convergent shifts are recasting the role of allergy diagnostics from confirmatory testing to a proactive enabler of personalized care.

Assessing how the 2025 tariff landscape will reshape supply chains, procurement behaviors, and regional manufacturing strategies across the diagnostics value chain

Policy actions and trade measures can have substantial ripple effects across the diagnostics supply chain, and the cumulative impact of tariff adjustments announced for 2025 will be observed across manufacturing, distribution, and laboratory operations. Tariffs on imported reagents, instrument components, and consumables raise the marginal cost of production for manufacturers that rely on international suppliers, which can translate into higher list prices and contracting pressures. For laboratories and end users, this increases the importance of supply chain resilience, inventory planning, and the negotiation of long-term supplier agreements.

Moreover, tariffs can incentivize regionalization of production and procurement, prompting multinational manufacturers to reassess sourcing footprints and consider nearshoring or dual-sourcing strategies to mitigate exposure. In parallel, procurement teams within hospitals, ambulatory centers, and diagnostics networks may shift purchasing priorities toward suppliers with domestic manufacturing capabilities or established tariff-mitigation measures. Over time, these adjustments may accelerate consolidation among suppliers who can absorb cost variability and maintain service levels, while smaller vendors and reagent suppliers face increased pressure to optimize operations or form strategic alliances to preserve market access.

Targeted segmentation insights linking test modalities, assay technologies, allergen categories, and end-user operational priorities to commercial opportunities

Segment insights are essential for tailoring product development, commercialization, and adoption strategies. Based on test type, diagnostic pathways range from skin-based modalities such as intradermal and patch testing to serum-based approaches including serum-specific IgE assays and skin prick testing; within serum analyses, chemiluminescence immunoassay and enzyme-linked immunosorbent assay methods coexist with legacy radioallergosorbent techniques, each offering distinct trade-offs in throughput, sensitivity, and laboratory compatibility. Based on technology, assay selection further differentiates the market because chemiluminescence platforms tend to favor automation and sensitivity, enzyme-linked immunosorbent assays deliver flexibility and cost efficiency for mid-volume labs, fluorescent enzyme immunoassays offer multiplexing advantages in some configurations, and radioallergosorbent methods remain relevant where established workflows persist.

Based on allergen type, diagnostic requirements vary substantially: contact allergens and drug allergens often require tailored exposure histories and specialized panels, food allergens demand high specificity to minimize unnecessary avoidance, and inhalant allergens benefit from well-validated component testing to guide immunotherapy. Based on end user, operational imperatives differ between ambulatory care centers prioritizing rapid, clinic-friendly workflows; diagnostic laboratories focusing on throughput, reproducibility, and result interpretation; and hospitals and clinics that integrate diagnostics into acute and chronic care pathways and require robust reporting for complex patients. These segmentation lenses highlight where clinical demand, laboratory capability, and commercial models intersect and where targeted investment can drive adoption.

How divergent regional clinical practices, regulatory landscapes, and infrastructure investments create distinct adoption pathways across global markets

Regional dynamics influence both clinical practice and commercial strategies, requiring nuanced approaches to product design, regulatory engagement, and channel management. In the Americas, robust clinical adoption of advanced serum-based assays is paired with concentrated laboratory networks and strong payer scrutiny, which together demand demonstrable clinical utility and efficient reimbursement pathways. In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and variable laboratory capacity mean that flexible product configurations, local partnerships, and support for decentralized testing can accelerate uptake, while regional clinical guidelines influence which allergen panels and assay formats are prioritized. In Asia-Pacific, rapid healthcare infrastructure investment, a growing prevalence of allergic conditions in urban centers, and diverse regulatory pathways create opportunities for both high-throughput centralized laboratories and point-of-care solutions adapted to local clinical workflows.

Taken together, these regional distinctions inform commercialization strategies, regulatory planning, and supply chain design, underscoring the importance of tailored evidence generation, localized service models, and partnerships with regional laboratory networks to achieve sustainable market penetration.

Key competitive behaviors and strategic priorities that determine which diagnostic providers will lead in laboratory adoption and clinical guideline integration

Competitive dynamics in allergy diagnostics are shaped by a mix of large diversified diagnostics firms, specialized allergy assay manufacturers, and agile niche players that focus on innovation or regional distribution. Established manufacturers invest in automation, multiplexing, and digital result interpretation to differentiate their portfolios and to meet laboratory demands for efficiency and integrated reporting. Specialized companies emphasize proprietary assay chemistries or clinical evidence supporting component-resolved diagnostics in order to drive adoption among allergists and tertiary care centers. Additionally, contract manufacturers and reagent suppliers play a critical role in maintaining supply continuity, particularly as laboratories seek partners capable of supporting validation and quality assurance under evolving regulatory expectations.

Strategic behaviors to watch include investments in partnerships with clinical networks and pharmacy chains for broader access, alliances with laboratory information system vendors to enhance result interoperability, and targeted evidence generation programs to secure favorable placement in clinical guidelines. Consolidation activity can be expected where scale enables improved pricing, distribution reach, and the ability to invest in next-generation assay development. New entrants that couple strong clinical data with scalable manufacturing and regulatory acumen will be well positioned to disrupt legacy business models.

Prioritized strategic initiatives for executives to strengthen evidence, interoperability, supply resilience, and go-to-market precision in allergy diagnostics

Industry leaders should prioritize a set of actionable initiatives to translate market dynamics into durable competitive advantage. First, invest in robust clinical evidence generation that demonstrates not only analytical performance but also clinical utility in guiding management decisions and reducing downstream healthcare utilization. Second, pursue platform interoperability and strong integration with laboratory information systems and electronic health records to streamline clinician workflows and enable value capture through decision support. Third, diversify supply chains and consider dual-sourcing or regional manufacturing arrangements to mitigate tariff exposure and ensure continuity of supply for critical reagents and instrument components.

Furthermore, adopt customer segmentation strategies that align commercial resources with the operational realities of ambulatory centers, high-throughput diagnostic laboratories, and integrated hospital systems. Complement product investments with scalable service offerings such as training, proficiency programs, and outcome tracking that lower adoption barriers. Finally, explore partnerships with therapeutics providers and allergy clinics to create bundled care pathways that link diagnostics to targeted interventions, thereby enhancing value propositions for payers and providers.

A transparent mixed-methods research approach integrating stakeholder interviews, regulatory review, and technical validation to underpin strategic recommendations

This analysis synthesizes findings derived from a rigorous mixed-methods research approach combining primary qualitative interviews with laboratory directors, practicing allergists, procurement leads, and industry executives alongside systematic secondary review of peer-reviewed literature, regulatory guidances, and technical documentation from assay manufacturers. Primary research emphasized triangulation across stakeholder groups to validate clinical workflows, assay preferences, and adoption barriers. Secondary sources provided context on technology performance characteristics, reimbursement environments, and historic regulatory precedents, which informed interpretation of stakeholder input and scenario development.

Data validation included cross-checking assay attributes and claimed performance characteristics against device labeling and regulatory summaries, while methodological transparency was maintained through clear documentation of inclusion criteria, interview protocols, and synthesis techniques. Limitations include variability across regional regulatory regimes and the evolving nature of trade policies, which may affect supply chain dynamics; these factors were addressed through scenario analysis and sensitivity checks to ensure robustness of recommendations. The result is a pragmatic evidence base designed to support strategic planning without relying on speculative forecasts.

Synthesis of actionable insights highlighting where technological advances, clinical expectations, and supply constraints intersect to inform strategic decisions

Allergy diagnostics is positioned at an inflection point where improved assay technologies, evolving clinical expectations, and supply chain realities converge to redefine how allergic disease is identified and managed. Precision in testing is enabling more effective patient stratification and targeted therapeutic pathways, while operational innovations are expanding capacity and improving turnaround. However, external pressures including trade policy shifts and regional heterogeneity in regulatory and reimbursement frameworks require proactive strategies around supply chain resilience, evidence generation, and localized commercialization.

Looking ahead, stakeholders who align product design with demonstrable clinical value, ensure interoperability with clinical systems, and adopt flexible manufacturing and distribution models will be best placed to capture opportunity and sustain adoption. Strategic collaboration between diagnostic providers, clinical networks, and payers will be crucial to translate diagnostic advances into measurable improvements in care pathways and patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increasing adoption of point-of-care allergy testing devices in primary care settings
• 5.2. Rapid growth of multiplex immunoassay platforms offering expanded allergen panels
• 5.3. Integration of artificial intelligence and machine learning for enhanced diagnostic accuracy in allergy testing
• 5.4. Rising prevalence of component-resolved diagnostics enabling personalized allergen profiling for targeted treatment
• 5.5. Expansion of home-based allergy testing kits with smartphone connectivity for remote patient monitoring
• 5.6. Emergence of molecular diagnostic techniques for precise identification of allergenic epitopes
• 5.7. Growing demand for telemedicine-based allergy consultations driven by improved digital health infrastructure
• 5.8. Regulatory landscape evolution impacting approval pathways for innovative allergy diagnostic solutions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allergy Diagnostics Market, by Test Type

• 8.1. Intradermal Test
• 8.2. Patch Test
• 8.3. Serum-Specific IgE Test
  • 8.3.1. Chemiluminescence Immunoassay
  • 8.3.2. Enzyme-Linked Immunosorbent Assay
  • 8.3.3. Radioallergosorbent Test
• 8.4. Skin Prick Test

9. Allergy Diagnostics Market, by Technology

• 9.1. Chemiluminescence Immunoassay
• 9.2. Enzyme-Linked Immunosorbent Assay
• 9.3. Fluorescent Enzyme Immunoassay
• 9.4. Radioallergosorbent Test

10. Allergy Diagnostics Market, by Allergen Type

• 10.1. Contact Allergen
• 10.2. Drug Allergen
• 10.3. Food Allergen
• 10.4. Inhalant Allergen

11. Allergy Diagnostics Market, by End User

• 11.1. Ambulatory Care Centers
• 11.2. Diagnostic Laboratories
• 11.3. Hospitals & Clinics

12. Allergy Diagnostics Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Allergy Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Allergy Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Siemens Healthineers AG
  • 15.3.2. Abbott Laboratories
  • 15.3.3. Beckman Coulter, Inc.
  • 15.3.4. Hycor Biomedical, LLC
  • 15.3.5. Thermo Fisher Scientific Inc.
  • 15.3.6. Becton Dickinson and Company
  • 15.3.7. Bio-Rad Laboratories, Inc.
  • 15.3.8. Eurofins Scientific SE
  • 15.3.9. Quest Diagnostics Incorporated
  • 15.3.10. Stallergenes Greer, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. ALLERGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. ALLERGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ALLERGY DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 126. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 127. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 128. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 129. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 130. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 131. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 132. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 133. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 134. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 135. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 136. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 137. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 140. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 141. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 142. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 143. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 144. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 145. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 146. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 147. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 148. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 149. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 152. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 153. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 154. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 155. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 156. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 157. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 158. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 159. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 160. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 173. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 176. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 177. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 178. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 179. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 180. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 181. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 182. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 183. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 184. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 185. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 188. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 189. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 190. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 192. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 193. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 194. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 195. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 196. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 197. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 200. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 201. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 202. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 203. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 204. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 205. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 206. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 207. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 212. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 213. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 214. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 215. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 216. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 217. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 218. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 219. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 226. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 227. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 228. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 229. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 230. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 231. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 232. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 233. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 238. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 239. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 240. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 241. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 242. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 243. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 244. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 245. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 246. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 247. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 250. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 251. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 252. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 253. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 254. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 255. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 256. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 257. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 258. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 259. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 262. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 263. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 264. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 265. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 266. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 267. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 268. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 269. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 274. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 275. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 276. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 277. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 278. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 279. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 280. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 281. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 282. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 283. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 286. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 287. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 288. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 289. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 290. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 291. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 292. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 293. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 294. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 295. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 298. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 299. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 300. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 301. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 302. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 303. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 304. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 305. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 306. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 307. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 308. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 309. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 310. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 311. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 312. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 313. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 314. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 315. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 316. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 317. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 318. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 319. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 320. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 321. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 322. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 323. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 324. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 325. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 326. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 327. BRAZIL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 328. BRAZIL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)

TABLE 32